BASKING RIDGE, N.J., June 18, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit (also known as REG1), its first-in-class, actively controllable injectable antithrombotic drug system, today announced the appointment of Drew Fromkin to the company's Board of Directors. Mr. Fromkin most recently served as President, Chief Executive Officer, of Clinical Data, Inc., prior to its acquisition by Forest Laboratories.
"We are delighted to welcome Drew to our Board of Directors," said Dennis Podlesak, Chairman of the Board of Regado Biosciences. "Drew brings a wealth of experience having been an accomplished CEO in multiple successful high growth life science companies. And Drew's appointment is timely, given his strong commercial background as Regado completes its Revolixys development program in 2015 and transforms into a viable commercial entity."
Mr. Fromkin joined Clinical Data, a global life sciences company, in late 2005. Under his leadership as CEO, Clinical Data was transformed from a traditional diagnostics business into a biopharmaceutical company with a pipeline of late-stage clinical candidates. Upon approval of its lead drug, Viibryd, a novel anti-depressant, Clinical Data was acquired by Forest Laboratories for $1.2B plus earn-out considerations.
Prior to joining Clinical Data, Mr. Fromkin served as Chief Executive Officer of Doctor Quality, Inc., until it was acquired by Quantros, Inc. Prior to Doctor Quality, Mr. Fromkin was CEO of Endo Surgical Devices. Prior to Endo, Mr. Fromkin held multiple senior executive positions at Merck-Medco Managed Care, a wholly owned subsidiary of Merck and Co. Mr. Fromkin holds a B.A. from Brandeis University.
Dennis Podlesak added, "We would like to thank Raphael Wisniewski, who is leaving our board after five years of excellent service for his numerous contributions and longstanding support of the company."
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, Revolixys™ Kit, is a two-component system consisting of pegnivacogin, an injectable anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary injectable oligonucleotide active control agent, anivamersen. Revolixys Kit is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with coronary artery disease (excluding those with ST-elevated myocardial infarction) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs. More information can be found at www.regadobio.com.
For more information on REGULATE-PCI, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01848106
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the progress of the REGULATE-PCI trial, enrollment in the REGULATE-PCI trial and the prospects for the completion of the REGULATE-PCI trial and any regulatory approval of Revolixys Kit and the successful commercialization of Revolixys Kit if approved. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from those projected in forward-looking statements include the "Risk Factors" described in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contacts:
SOURCE Regado Biosciences, Inc.